Body fluid and structural imaging biomarkers give information on neurodegeneration. The relationship over time is not known in multiple sclerosis.
Objective:
To investigate the temporal relationship of elevated cerebrospinal fluid (CSF) neurofilament (Nf) protein levels, a biomarker for axonal loss, with magnetic resonance imaging (MRI) atrophy measures.
Methods:
In patients with multiple sclerosis, CSF Nf heavy chain (NfH) phosphoform levels were quantified at baseline and dichotomised into ‘normal’ and ‘high’. Atrophy was assessed by MRI at baseline and 15-year follow-up using SIENAX and FreeSurfer software.
Results:
High baseline CSF NfHSMI35 levels predicted pronounced atrophy at 15-year follow-up (odds ratio (OR): 36, p < 0.01), in the absence of baseline brain atrophy (OR: 28, p < 0.05), for the averaged MRI normalised brain volume (1.44 L vs 1.33 L, p < 0.05), normalised grey matter volume (0.77 L vs 0.69 L, p < 0.01) and putamen (12.7 mL vs 10.7 mL, p < 0.05). Region-specific calculations including the spinal cord showed that a power of >80% is reached with 14–50 patients.
Conclusion:
These data suggest that high CSF NfH levels are an early predictor of later brain and spinal cord atrophy using structural imaging biomarkers and can be investigated in reasonably sized patient cohorts.
FrieseMASchattlingBFuggerL. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol2014; 10: 225–238.
4.
PetzoldAPlantGT. Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev2014; 13: 539–545.
5.
ComabellaMMontalbanX. Body fluid biomarkers in multiple sclerosis. Lancet Neurol2014; 13: 113–126.
6.
PetzoldATisdallMMGirbesAR. In vivo monitoring of neuronal loss in traumatic brain injury: A microdialysis study. Brain2011; 134: 464–483.
7.
KhourySBakshiR. Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. Ann Neurol2010; 68: 778–779.
8.
GassARoccaMAAgostaF. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol2015; 14: 443–454.
9.
FilippiMPreziosaPRoccaMA. Magnetic resonance outcome measures in multiple sclerosis trials: Time to rethink?Curr Opin Neurol2014; 27: 290–299.
10.
VigevenoRMWiebengaOTWattjesMP. Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration. J Magn Reson Imaging2012; 36: 1–19.
11.
EikelenboomMJPetzoldALazeronRH. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology2003; 60: 219–223.
12.
PetzoldAEikelenboomMJKeirG. Axonal damage accumulates in the progressive phase of multiple sclerosis: Three year follow up study.J Neurol Neurosurg Psychiatry2005; 76:206–211.
13.
PetzoldA. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up. J Neurol Neurosurg Psychiatry2015; 88: 1388–1390.
14.
BalkLJSteenwijkMDTewarieP. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. J Neurol Neurosurg Psychiatry2015; 86: 419–424.
15.
McDonaldWICompstonAEdanG. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50: 121–127.
16.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology1983; 33: 1444–1452.
17.
SteenwijkMDDaamsMPouwelsPJW. What explains gray matter atrophy in long-standing multiple sclerosis?Radiology2014; 272: 832–842.
18.
SteenwijkMDPouwelsPJWDaamsM. Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). Neuroimage Clin2013; 3: 462–469.
19.
ChardDTJacksonJSMillerDH. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging2010; 32: 223–228.
20.
DaamsMWeilerFSteenwijkMD. Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability. Mult Scler2014; 20: 1860–1865.
21.
LiuYLukasCSteenwijkMD. Multicenter validation of mean upper cervical cord area measurements from head 3D T1-weighted MR imaging in patients with multiple sclerosis. Am J Neuroradiol. Epub ahead of print 10December2015. DOI: 10.3174/ajnr.A4635.
22.
PetzoldAKeirGGreenAJE. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods2003; 278: 179–190.
23.
FreedmanMSThompsonEJDeisenhammerF. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: A consensus statement. Arch Neurol2005; 62: 865–870.
24.
StangelMFredriksonSMeinlE. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol2013; 9: 267–276.
25.
PetzoldA. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss. J Neurol Sci2005; 233: 183–198.
26.
TrappBDPetersonJPRansohoffRM. Axonal transection in the lesions of multiple sclerosis. N Eng J Med1998; 338: 278–285.
27.
GriffinJSGeorgeEBHsiehST. Chapter 20. Axonal degeneration and disorders of the axonal cytoskeleton. In: WaxmanSGKocsisJDStysPK (eds) The axon: structure, function and pathophysiology. New York: Oxford University Press, 1995, pp. 375–390.
28.
AvellinoAMHartDDaileyAT. Differential macrophage responses in the peripheral and central nervous system during Wallerian degeneration of axons. Exp Neurol1995; 136: 183–198.
29.
GeorgeRGriffinJW. Delayed macrophage responses and myelin clearance during Wallerian degeneration in the central nervous system: The dorsal radiculotomy model. Exp Neurol1994; 129: 225–236.
30.
StollGGriffinJWLiCY. Wallerian degeneration in the peripheral nervous system: Participation of both Schwann cells and macrophages in myelin degradation. J Neurocytol1989; 18: 671–683.
31.
StollGTrappBDGriffinJW. Macrophage function during Wallerian degeneration of rat optic nerve: Clearance of degenerating myelin and Ia expression. J Neurosci1989; 9: 2327–2335.
32.
GabilondoIMartnez-LapiscinaEHMartnez-HerasE. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol2014; 75: 98–107.
33.
PetzoldARejdakKPlantGT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry2004; 75: 1178–1180.
34.
ModvigSDegnMSanderB. Cerebrospinal fluid neurofilament light chain levels predict visual outcome after optic neuritis. Mult Scler2016; 22(5): 590–598.
35.
PetzoldAKeirGWarrenJ. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis2007; 4: 185–194.
